Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sutro BiopharmaSTRO -4.79%45 Operating Cash Flow per Share is $-13.07 as of Jun. 2026. GuruFocus rates STRO with a GF Score™ of 45/100 and a GF Value™ of $5.30 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,133 Biotechnology companies, Sutro Biopharma ranks worse than 88261.17% on this metric.
Sutro Biopharma's operating cash flow per share for the
three
months ended in Jun. 2026 was $-2.31.
Sutro Biopharma's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2026 was $-13.07.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Sutro Biopharma's Operating Cash Flow per Share or its related term are showing as below:
During the past 10 years, Sutro Biopharma's highest 3-Year average Operating Cash Flow per Share Growth Rate was 26.70% per year. The lowest was -14.70% per year. And the median was -4.00% per year.
STRO's 3-Year OCF Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 17 * Ranked among companies with meaningful 3-Year OCF Growth Rate only.
Sutro Biopharma Operating Cash Flow per Share Related Terms
Sutro Biopharma Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for Sutro Biopharma's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sutro Biopharma Operating Cash Flow per Share Chart
STRO vs ABEO, IKT, AGEN: Operating Cash Flow per Share Comparison
For the Biotechnology subindustry, Sutro Biopharma's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sutro Biopharma Price-to-Operating-Cash-Flow vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sutro Biopharma's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Sutro Biopharma's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.07
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of $-13.07 mean?
Sutro Biopharma (STRO) has a Operating Cash Flow per Share of $-13.07 as of Jun. 2026. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Sutro Biopharma and its competitors. According to the industry distribution chart, Sutro Biopharma ranks #999999 out of 1133 companies in the Biotechnology industry.
Is Sutro Biopharma's Operating Cash Flow per Share too high?
Sutro Biopharma's current Operating Cash Flow per Share is $-13.07. Based on the distribution chart, Sutro Biopharma ranks #999999 out of 1133 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sutro Biopharma has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sutro Biopharma's Operating Cash Flow per Share compare to ABEO and IKT?
According to the Biotechnology industry distribution chart, Sutro Biopharma ranks #999999 out of 1133 companies for Operating Cash Flow per Share. This places Sutro Biopharma in the lower half of its industry. The industry median Operating Cash Flow per Share is 17.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Biotechnology company?
The median Operating Cash Flow per Share among Biotechnology companies is 17.00, based on 1,133 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Sutro Biopharma and its competitors. For the Biotechnology industry, the median Operating Cash Flow per Share is 17.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sutro Biopharma's current Operating Cash Flow per Share is $-13.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sutro Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Sutro Biopharma (STRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.30, compared to a current price of $19.12 — trading 260.8% above its estimated fair value. The current Operating Cash Flow per Share is $-13.07. Sutro Biopharma's overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Sutro Biopharma (STRO), the current Operating Cash Flow per Share is $-13.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sutro Biopharma (STRO) Overvalued in 2026?
Based on GuruFocus' analysis, Sutro Biopharma stock appears to be overvalued.
The current stock price of $19.12 is trading 260.8% above its estimated GF Value™ of $5.30.
GuruFocus considers Sutro Biopharma to be Significantly Overvalued.
Key valuation signals for STRO:
Operating Cash Flow per Share: $-13.07
GF Value™: $5.30 vs. price of $19.12 (260.8% above fair value)
No single metric tells the full story. See the STRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
45GF Score
Get the complete analysis for STRO
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STRO has been successfully added to your 
